Literature DB >> 34661736

Clinical findings in eyes with BEST1-related retinopathy complicated by choroidal neovascularization.

Mai Miyagi1, Jun Takeuchi1, Yoshito Koyanagi1,2, Kei Mizobuchi3, Takaaki Hayashi3, Yasuki Ito1,4, Hiroko Terasaki1, Koji M Nishiguchi1, Shinji Ueno5.   

Abstract

PURPOSE: To determine the characteristics of eyes diagnosed with Best vitelliform macular dystrophy (BVMD) and autosomal recessive bestrophinopathy (ARB) complicated by choroidal neovascularization (CNV).
METHODS: This was a retrospective, multicenter observational case series. Fourteen genetically confirmed BVMD patients and 9 ARB patients who had been examined in 2 ophthalmological institutions in Japan were studied. The findings in a series of ophthalmic examinations including B-scan optical coherence tomography (OCT) and OCT angiography (OCTA) were reviewed.
RESULTS: CNV was identified in 5 eyes (17.9%) of BVMD patients and in 2 eyes (11.1%) of ARB patients. Three of 5 eyes with BVMD were classified as being at the vitelliruptive stage and 2 eyes at the atrophic stage. The CNV in 2 BVMD eyes were diagnosed as exudative because of acute visual acuity reduction, retinal hemorrhage, and intraretinal fluid, while the CNV in 3 BVMD eyes and 2 ARB eyes were diagnosed as non-exudative. The visual acuity of the two eyes with exudative CNV did not improve despite anti-VEGF treatments. None of the eyes with non-exudative CNV had a reduction of their visual acuity for at least 4 years. All of the CNV were located within hyperreflective materials which were detected in 16 eyes (57.1%) of the BVMD eyes and in 7 eyes (38.9%) of the ARB eyes.
CONCLUSIONS: CNV is a relatively common complication in BEST1-related retinopathy in Asian population as well. The prognosis of eyes with exudative CNV is not always good, and OCTA can detect CNV in eyes possessing hyperreflective materials.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Autosomal recessive bestrophinopathy; Best vitelliform macular dystrophy; Choroidal neovascularization; Hyperreflective materials; Optical coherence tomography angiography

Mesh:

Substances:

Year:  2021        PMID: 34661736     DOI: 10.1007/s00417-021-05447-y

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  22 in total

1.  Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium.

Authors:  A D Marmorstein; L Y Marmorstein; M Rayborn; X Wang; J G Hollyfield; K Petrukhin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

2.  Variant phenotype of Best vitelliform macular dystrophy associated with compound heterozygous mutations in VMD2.

Authors:  Patrik Schatz; Joakim Klar; Sten Andréasson; Vesna Ponjavic; Niklas Dahl
Journal:  Ophthalmic Genet       Date:  2006-06       Impact factor: 1.803

Review 3.  Bestrophin 1 and retinal disease.

Authors:  Adiv A Johnson; Karina E Guziewicz; C Justin Lee; Ravi C Kalathur; Jose S Pulido; Lihua Y Marmorstein; Alan D Marmorstein
Journal:  Prog Retin Eye Res       Date:  2017-01-30       Impact factor: 21.198

4.  Clinical and Genetic Findings of Autosomal Recessive Bestrophinopathy in Japanese Cohort.

Authors:  Ayami Nakanishi; Shinji Ueno; Takaaki Hayashi; Satoshi Katagiri; Taro Kominami; Yasuki Ito; Tamaki Gekka; Yoichiro Masuda; Hiroshi Tsuneoka; Kei Shinoda; Akito Hirakata; Makoto Inoue; Kaoru Fujinami; Kazushige Tsunoda; Takeshi Iwata; Hiroko Terasaki
Journal:  Am J Ophthalmol       Date:  2016-05-07       Impact factor: 5.258

5.  Identification of the gene responsible for Best macular dystrophy.

Authors:  K Petrukhin; M J Koisti; B Bakall; W Li; G Xie; T Marknell; O Sandgren; K Forsman; G Holmgren; S Andreasson; M Vujic; A A Bergen; V McGarty-Dugan; D Figueroa; C P Austin; M L Metzker; C T Caskey; C Wadelius
Journal:  Nat Genet       Date:  1998-07       Impact factor: 38.330

6.  Use of Intravitreal Bevacizumab in a 9-Year-Old Child with Choroidal Neovascularization Associated with Autosomal Recessive Bestrophinopathy.

Authors:  Rumana N Hussain; Fatema L Shahid; Theodoros Empeslidis; Soon Wai Ch'ng
Journal:  Ophthalmic Genet       Date:  2015       Impact factor: 1.803

7.  CHANGES OF CONE PHOTORECEPTOR MOSAIC IN AUTOSOMAL RECESSIVE BESTROPHINOPATHY.

Authors:  Ayami Nakanishi; Shinji Ueno; Takaaki Hayashi; Satoshi Katagiri; Yasuki Ito; Taro Kominami; Kaoru Fujinami; Kazushige Tsunoda; Takeshi Iwata; Hiroko Terasaki
Journal:  Retina       Date:  2020-01       Impact factor: 4.256

Review 8.  The spectrum of ocular phenotypes caused by mutations in the BEST1 gene.

Authors:  Camiel J F Boon; B Jeroen Klevering; Bart P Leroy; Carel B Hoyng; Jan E E Keunen; Anneke I den Hollander
Journal:  Prog Retin Eye Res       Date:  2009-04-16       Impact factor: 21.198

9.  Biallelic mutation of BEST1 causes a distinct retinopathy in humans.

Authors:  Rosemary Burgess; Ian D Millar; Bart P Leroy; Jill E Urquhart; Ian M Fearon; Elfrida De Baere; Peter D Brown; Anthony G Robson; Genevieve A Wright; Philippe Kestelyn; Graham E Holder; Andrew R Webster; Forbes D C Manson; Graeme C M Black
Journal:  Am J Hum Genet       Date:  2008-01       Impact factor: 11.025

10.  Disease-causing mutations associated with four bestrophinopathies exhibit disparate effects on the localization, but not the oligomerization, of Bestrophin-1.

Authors:  Adiv A Johnson; Yong-Suk Lee; Andrew J Chadburn; Paolo Tammaro; Forbes D Manson; Lihua Y Marmorstein; Alan D Marmorstein
Journal:  Exp Eye Res       Date:  2014-02-19       Impact factor: 3.467

View more
  2 in total

1.  Bilateral consecutive choroidal neovascularization in Best vitelliform macular dystrophy.

Authors:  Sandra Hoyek; Lisa Y Lin; Lindsay Klofas Kozek; Efren Gonzalez; Farrah Rajabi; Nimesh A Patel
Journal:  Proc (Bayl Univ Med Cent)       Date:  2022-05-05

2.  Polypoidal choroidal vasculopathy in a patient with DMPK-associated myotonic dystrophy.

Authors:  Yuka Iida; Takaaki Hayashi; Teruaki Tokuhisa; Kei Mizobuchi; Shusaku Omoto; Tadashi Nakano
Journal:  Doc Ophthalmol       Date:  2022-03-13       Impact factor: 1.854

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.